In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma

Oncogene

Volumn 26, Issue 30, 2007, Pages 4428-4434

  Narla, G ^a   Kremer Tal, S ^a   Matsumoto, N ^a   Zhao, X ^a   Yao, S ^a   Kelley, K ^a   Tarocchi, M ^a   Friedman, S L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Haploinsufficiency; KLF6; Kruppel like factor; p21; Tumor suppressor gene

Indexed keywords

CYCLINE; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; PROTEIN P21; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BODY SIZE; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPERIMENTAL MODEL; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC MODEL; HAPLOTYPE; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER SIZE; LIVER WEIGHT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIVER; LIVER NEOPLASMS; MICE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER;

MUS;

EID: 34347358573     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210223     Document Type: Article

References (36)

1. Alberici P, Jagmohan-Changur S, De Pater E, Van Der Valk M, Smits R, Hohenstein P et al. (2006). Smad4 haploinsufficiency in mouse models for intestinal cancer. Oncogene 25: 1841-1851.
2. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS et al. (2004). Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor proteinthrough interactionwith cyclin D1. Cancer Res 64: 3885-3891.
3. Bieker JJ. (2001). Kruppel-like factors: three fingers in many pies. J Biol Chem 276: 34355-34358.
4. Bissell DM, Guzelian PS. (1980). Phenotypic stability of adult rat hepatocytes inprimary monolayer culture. Ann N Y Acad Sci 349: 85-98.
5. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M et al. (2002). Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between sp1 and KLF6: their potential role in the response to vascular injury. Blood 100: 4001-4010.
6. Boyault S, Herault A, Balabaud C, Zucman-Rossi J. (2005). Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. Hepatology 41: 681-682 author reply 682-683.
7. Chen C, Hyytinen E R, Sun X, Helin HJ, Koivisto PA, Frierson HF et al. (2003). Deletion, mutation, and loss of expressionof KLF6 inhumanprostate cancer. Am J Pathol 162: 1349-1354.
8. Chen HK, Liu XQ, Lin J, Chen TY, Feng QS, Zeng YX. (2002). Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 21: 1047-1050.
9. Cho YG, Kim CJ, Park CH, Yang YM, Kim SY, Nam SW et al. (2005). Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 24: 4588-4590.
10. Difeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE et al. (2006). E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 25: 6026-6031.
11. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL et al. (2006). Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 12: 3730-3739.
12. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. (1993). Waf1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
13. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RH, Gerald WL. (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913-923.
14. Ito G, Uchiyama M., Kondo M, Mori S, Usami N, Maeda O et al. (2004). Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 64: 3838-3843.
15. Jeng YM, Hsu HC. (2003). KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 105: 625-629.
16. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I et al. (2004). Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 149: 98-106.
17. Kim Y, Ratziu V, Choi SG, Lalazar A, Theiss G, Dang Q et al. (1998). Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 273: 33750-33758.
18. Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD et al. (2004). Suppressionof glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23: 5077-5083.
19. Kremer-Tal S, Narla G, ChenY, Hod E, DiFeo A, Yea S et al. (2006). Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol Nov 27 [Epub ahead of print].
20. Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A et al. (2004). Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) inhepatocellular carcinoma. Hepatology 40: 1047-1052.
21. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N et al. (2001). Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98: 11563-11568.
22. Lee JS, Chu IS, Heo J, Calvisi DF, SunZ, Roskams T et al. (2004). Classificationan d prediction of survival inhepatocellular carcinoma by gene expression profiling. Hepatology 40: 667-676.
23. Matsumoto N, Kubo A, Liu H, Akita K, Laub F, Ramirez F et al. (2006). Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107: 1357-1365.
24. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E et al. (2005). A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65: 1213-1222.
25. Narla G, FriedmanSL, Martignetti JA. (2003). Kruppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol 162: 1047-1052.
26. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC et al. (2001). KLF6, a candidate tumor suppressor gene mutated inpr ostate cancer. Science 294: 2563-2566.
27. Pan XC, Chen Z, Chen F, Chen XH, Jin HY, Xu XY. (2006). Inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) by mutationor decreased expressionin hepatocellular carcinomas. J Zhejiang Univ Sci B 7: 830-836.
28. Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S et al. (2004). Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126: 1090-1103.
29. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
30. Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, ChattonB, Bocco JL. (2004). A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene 23: 8196-8205.
31. Song J, Kim CJ, Cho YG, Kim SY, Nam SW, Lee SH et al. (2006). Genetic and epigenetic alterations of the KLF6 gene inhepatocellular carcinoma. J Gastroenterol Hepatol 21: 1286-1289.
32. Venkatachalam S, Tyner SD, Pickering CR, Boley S, Recio L, French JE et al. (2001). Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenity testing. Toxicol Pathol 29(Suppl): 147-154.
33. Walthall K, Cappon GD, Hurtt ME, Zoetis T. (2005). Postnatal development of the gastrointestinal system: A species comparison. Birth Defects Res B Dev Reprod Toxicol 74: 132-156.
34. Wang SP, Chen XP, Qiu FZ. (2004). A candidate tumor suppressor gene mutated in primary hepatocellular carcinoma: Kruppel-like factor 6. Zhonghua Wai Ke Za Zhi 42: 1258-1261.
35. Warke VG, Nambiar MP, Krishnan S, Tenbrock K, Geller DA, Koritschoner NP et al. (2003). Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem 278: 14812-14819.
36. Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T. (1996). Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev 10: 245-260.